Table 3.
Antimicrobial efficacy of different nanocomposites in PMMA and PLA matrices.
| Author and Year | Nanoparticle Used | Concentration (%) | Microorganisms Tested | |
|---|---|---|---|---|
| Kamonkhantikul et al., 2017 (10). | Zinc Oxide Nanofiller | 2% - 5% | Streptococcus mutans, Candida albicans, Escherichia coli | |
| Shafiee Nasab et al. 2018 (20). | Nano-PLA, Zinc Oxide Nanoparticles | 1%, 3%, 5% | Staphylococcus aureus, Candida albicans, Escherichia coli, Pseudomonas aeruginosa | |
| Lipovsky et al., 2011(6). | ZnO, ZnO (various sizes), ZnO + Histidine, ZnO + Blue Light | 0.1 mg/ml (ZnO), Various sizes (ZnO), 0.05 mg/ml (ZnO + Histidine), 0.1 mg/ml (ZnO + Blue Light) | Candida albicans | |
| Mousavi et al., 2020 (5). | Silver (Ag), Zinc Oxide (ZnO), Chitosan | 0.625% to 5% | Candida albicans, Enterococcus faecalis, Pseudomonas aeruginosa, Streptococcus mutans | |
| Abd Alwahab et al. 2020 (21). | Nano ZrO2 | 0.02%, 0.04%, 0.06%, 0.08%, 1.0% | Not tested | |
| Nano ZnO | 0.02%, 0.04%, 0.06%, 0.08%, 1.0% | |||
| Fahmi et al. 2019 (16). | Zinc Oxide | 1%, 2%, 3% | Not tested | |
| Collares et al. 2020 (22). | Zinc Oxide Nanostructures (ZnO-NN) | 20%, 30%, 40% | Enterococcus faecalis | |
| Raj et al. 2018 (23). | Zinc oxide (ZnO) | 1%, 2%, and 3% | Streptococcus mutans and Candida albicans |